This is Hansa
Our therapeutic areas
Our technology platform
Our pipeline and products
Career
Investors
Media
Contacts
Klaus Sindahl
Head of Investor Relations
Mobile: +46 (0) 709 298 269
Email: klaus.sindahl@hansabiopharma.com